AbbVie’s Rinvoq clears second Phase 3 trial in hair loss diseasenews2025-08-21T18:31:28+00:00August 21st, 2025|Endpoints News|
Nicox eyes FDA submission as ocular hypertension drug passes Phase 3news2025-08-21T15:18:46+00:00August 21st, 2025|Endpoints News|
Dynavax says its shingles shot was ‘comparable’ to Shingrix in early readoutnews2025-08-21T12:00:17+00:00August 21st, 2025|Endpoints News|
Prader-Willi syndrome is not a zero-sum game. There’s room for many winnersnews2025-08-21T11:00:48+00:00August 21st, 2025|Endpoints News|
Celldex shelves antibody in swallowing disorder, looks to itching readouts next yearnews2025-08-20T10:49:13+00:00August 20th, 2025|Endpoints News|
George Church’s lab gets closer to creating human eggs in a dish, and a new startup plans to finish the jobnews2025-08-19T15:16:55+00:00August 19th, 2025|Endpoints News|
Sensorium raises $25M for clinical tests of succulent-derived drug for anxietynews2025-08-19T14:00:51+00:00August 19th, 2025|Endpoints News|
Updated: Viking’s stock tanks as mid-stage obesity pill disappoints on efficacy, safetynews2025-08-19T11:30:31+00:00August 19th, 2025|Endpoints News|
How the draft MAHA Commission recommendations may impact pharmanews2025-08-18T19:17:21+00:00August 18th, 2025|Endpoints News|
Conflicts among US vaccine advisors declined through 2024, new research showsnews2025-08-18T15:00:37+00:00August 18th, 2025|Endpoints News|
